{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:56:01Z","timestamp":1787943361398,"version":"build-2784847793"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Safer supply programs were implemented in Canada to provide pharmaceutical-grade alternatives to the toxic unregulated drug supply. While research shows clinical benefits and reduced overdose mortality among safer supply patients, medication diversion remains a concern.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine provider (prescribing clinicians and allied health professionals) and patient perspectives on diversion of opioids prescribed in safer supply programs.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In 2021, qualitative interviews and sociodemographic questionnaires were conducted with patients and providers across 4 safer supply programs in Ontario, Canada. Interviews with 21 providers (physicians, nurse practitioners, and allied health professionals) and 52 patients examined experiences implementing safer supply or receiving care. Initial data analysis was conducted from December 2021 to March 2022, and the subanalysis focused on diversion was conducted from December 2023 to March 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Participation in safer supply program as a patient or provider.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Data about diversion were coded, extracted, and thematically analyzed.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 52 patient participants, 29 (55.8%) were men and 23 (44.2%) were women; 1 was Black (1.9%), 9 (17.3%) were Indigenous, 1 was Latino (1.9%), and 41 (78.8%) were White; and the mean (SD) age was 46.5 (9.6) years. Of 21 provider participants, 6 (28.6%) were men, 13 (61.9%) were women, and 2 (9.5%) were nonbinary; and the mean (SD) age was 37.6 (7.6) years. Participants characterized diversion as a spectrum ranging from no diversion, to occasional medication sharing and loss, to selling all prescribed doses of safer supply (considered rare and easy to detect). Most patients reported they consumed all or most of their prescribed medications and rarely shared or sold their doses. However, providers and patient participants shared that people might share, trade, and\/or sell some of their medications with other opioid-using people for multiple reasons. Most prominent reasons for diversion were (1) compassionate sharing with intimate partners and friends to manage withdrawal and overdose risk; (2) selling or trading medications to address their own unmet substance use needs (eg, high opioid tolerance); and (3) medication loss due to poverty, homelessness, and associated vulnerabilities to theft and coercion. Programs used nonpunitive urine drug screening practices and patient self-report to monitor medication use. When diversion was identified, providers described using nonjudgmental conversations to understand patients\u2019 needs and develop mitigation strategies that addressed underlying reasons for diversion, including changing doses and medications prescribed to better match patients\u2019 needs, enrolling eligible intimate partners, and developing safety plans to mitigate vulnerabilities to theft and coercion.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Diversion encompasses a wide spectrum of practices (selling, sharing, and loss of medications), and occurs for complex reasons that surveillance and punitive measures are unlikely to mitigate. Diversion may be best addressed by expanding medication options to better match patients\u2019 diverse substance use needs and high tolerance, alongside wraparound social supports.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.51988","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T16:00:40Z","timestamp":1734537640000},"page":"e2451988","source":"Crossref","is-referenced-by-count":15,"title":["Perspectives on Diversion of Medications From Safer Opioid Supply Programs"],"prefix":"10.1001","volume":"7","author":[{"given":"Michelle","family":"Olding","sequence":"first","affiliation":[{"name":"Division of Social and Behavioural Health Sciences, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Rudzinski","sequence":"additional","affiliation":[{"name":"Division of Social and Behavioural Health Sciences, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"},{"name":"School of Social Work, University of Windsor, Windsor, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Division of Social and Behavioural Health Sciences, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Kolla","sequence":"additional","affiliation":[{"name":"Population Health and Applied Health Sciences, Faculty of Medicine, Memorial University, St John\u2019s, Newfoundland and Labrador, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"German","sequence":"additional","affiliation":[{"name":"Department of Health, Behavior, and Society, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sereda","sequence":"additional","affiliation":[{"name":"London InterCommunity Health Centre, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Strike","sequence":"additional","affiliation":[{"name":"Division of Social and Behavioural Health Sciences, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Guta","sequence":"additional","affiliation":[{"name":"School of Social Work, University of Windsor, Windsor, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"4","key":"zoi241449r2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis.","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr Opin Psychiatry"},{"key":"zoi241449r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103237","article-title":"Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: a national qualitative assessment in Canada.","volume":"93","author":"Ali","year":"2021","journal-title":"Int J Drug Policy"},{"issue":"5","key":"zoi241449r4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11916-024-01211-z","article-title":"Xylazine: a drug adulterant of clinical concern.","volume":"28","author":"Edinoff","year":"2024","journal-title":"Curr Pain Headache Rep"},{"key":"zoi241449r5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis.","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"zoi241449r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109427","article-title":"Variability in the unregulated opioid market in the context of extreme rates of overdose.","volume":"235","author":"Larnder","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"zoi241449r7","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/add.14664","article-title":"Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic.","volume":"114","author":"Irvine","year":"2019","journal-title":"Addiction"},{"issue":"7","key":"zoi241449r8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.2105\/AJPH.2023.307320","article-title":"At the crossroads in the opioid overdose epidemic: will evidence-based \u201cradical\u201d but rational drug policy strategies prevail?","volume":"113","author":"Stahler","year":"2023","journal-title":"Am J Public Health"},{"issue":"3","key":"zoi241449r9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2105\/AJPH.2023.307559","article-title":"Looking back on COVID-19 and the evolving drug overdose crisis: updated trends through 2022.","volume":"114","author":"Friedman","year":"2024","journal-title":"Am J Public Health"},{"issue":"2","key":"zoi241449r10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/00952990.2023.2170807","article-title":"Iteration is not solving the opioid crisis, it\u2019s time for transformation.","volume":"49","author":"Dunn","year":"2023","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"36","key":"zoi241449r12","doi-asserted-by":"publisher","first-page":"E1233","DOI":"10.1503\/cmaj.220892","article-title":"Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario.","volume":"194","author":"Gomes","year":"2022","journal-title":"CMAJ"},{"key":"zoi241449r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103742","article-title":"\u201cCOVID just kind of opened a can of whoop-ass\u201d: the rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada.","volume":"106","author":"Glegg","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"S2","key":"zoi241449r14","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2105\/AJPH.2021.306692","article-title":"Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021.","volume":"112","author":"McNeil","year":"2022","journal-title":"Am J Public Health"},{"key":"zoi241449r15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104339","article-title":"Prescribed safer opioid supply: a scoping review of the evidence.","volume":"125","author":"Ledlie","year":"2024","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi241449r16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12954-023-00817-7","article-title":"Impact of safer supply programs on injection practices: client and provider experiences in Ontario, Canada.","volume":"20","author":"Gagnon","year":"2023","journal-title":"Harm Reduct J"},{"issue":"7","key":"zoi241449r17","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1111\/dar.13745","article-title":"\u2018I don\u2019t chase drugs as much anymore, and I\u2019m not dead\u2019: client reported outcomes associated with safer opioid supply programs in Ontario, Canada.","volume":"42","author":"Schmidt","year":"2023","journal-title":"Drug Alcohol Rev"},{"key":"zoi241449r18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076336","article-title":"Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study.","volume":"384","author":"Slaunwhite","year":"2024","journal-title":"BMJ"},{"key":"zoi241449r19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104389","article-title":"Acceptability and anticipated effectiveness of a safe supply of opioids, among people who inject opioids in King County, WA.","volume":"127","author":"Palayew","year":"2024","journal-title":"Int J Drug Policy"},{"issue":"4","key":"zoi241449r20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.15288\/jsad.23-00054","article-title":"\u201cSafe supply\u201d initiatives: are they a recipe for harm through reduced health care input and supply-induced toxicity and overdose?","volume":"84","author":"Roberts","year":"2023","journal-title":"J Stud Alcohol Drugs"},{"key":"zoi241449r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104423","article-title":"Mapping a moral panic: news media narratives and medical expertise in public debates on safer supply, diversion, and youth drug use in Canada.","volume":"127","author":"Michaud","year":"2024","journal-title":"Int J Drug Policy"},{"issue":"3","key":"zoi241449r22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1465-3362.2010.00283.x","article-title":"Definitions related to the use of pharmaceutical opioids: extramedical use, diversion, non-adherence and aberrant medication-related behaviours.","volume":"30","author":"Larance","year":"2011","journal-title":"Drug Alcohol Rev"},{"issue":"5","key":"zoi241449r23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/ADM.0000000000000045","article-title":"A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world.","volume":"8","author":"Lofwall","year":"2014","journal-title":"J Addict Med"},{"key":"zoi241449r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103515","article-title":"\u2018Keeping a lid on it\u2019: Exploring \u2018problematisations\u2019 of prescribed medication in prisons in the UK.","volume":"100","author":"Duke","year":"2022","journal-title":"Int J Drug Policy"},{"key":"zoi241449r25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.drugalcdep.2018.02.010","article-title":"The source and diversion of pharmaceutical drugs for non-medical use: a systematic review and meta-analysis.","volume":"186","author":"Hulme","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"zoi241449r26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1477-7517-10-24","article-title":"\u2018Diversion\u2019 of methadone or buprenorphine: \u2018harm\u2019 versus \u2018helping\u2019.","volume":"10","author":"Havnes","year":"2013","journal-title":"Harm Reduct J"},{"issue":"12","key":"zoi241449r27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167499","article-title":"Abuse and diversion of immediate release opioid analgesics as compared to extended release formulations in the United States.","volume":"11","author":"Iwanicki","year":"2016","journal-title":"PLoS One"},{"key":"zoi241449r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108651","article-title":"Beyond harm-producing versus harm-reducing: A qualitative meta-synthesis of people who use drugs\u2019 perspectives of and experiences with the extramedical use and diversion of buprenorphine.","volume":"135","author":"Sud","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"zoi241449r29","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.drugpo.2012.10.003","article-title":"Methadone diversion as a protective strategy: the harm reduction potential of \u2018generous constraints\u2019.","volume":"24","author":"Harris","year":"2013","journal-title":"Int J Drug Policy"},{"key":"zoi241449r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108418","article-title":"Examining factors that shape use and access to diverted prescription opioids during an overdose crisis: a qualitative study in Vancouver, Canada.","volume":"130","author":"Bardwell","year":"2021","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"zoi241449r31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1080\/10826084.2021.2019775","article-title":"\u201cI\u2019m not a good drug dealer\u201d: styles of buprenorphine diversion in a multisite qualitative study.","volume":"57","author":"McLean","year":"2022","journal-title":"Subst Use Misuse"},{"key":"zoi241449r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104023","article-title":"Risk mitigation guidance and safer supply prescribing among young people who use drugs in the context of COVID-19 and overdose emergencies.","volume":"115","author":"Giang","year":"2023","journal-title":"Int J Drug Policy"},{"issue":"1","key":"zoi241449r33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12954-023-00776-z","article-title":"Safer opioid supply: qualitative program evaluation.","volume":"20","author":"Haines","year":"2023","journal-title":"Harm Reduct J"},{"key":"zoi241449r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109109","article-title":"The use of diverted pharmaceutical opioids is associated with reduced risk of fentanyl exposure among people using unregulated drugs in Vancouver, Canada.","volume":"228","author":"Socias","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi241449r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.113986","article-title":"\u201cPeople need them or else they\u2019re going to take fentanyl and die\u201d: a qualitative study examining the \u2018problem\u2019 of prescription opioid diversion during an overdose epidemic.","volume":"279","author":"Bardwell","year":"2021","journal-title":"Soc Sci Med"},{"issue":"6","key":"zoi241449r36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.5055\/jom.2015.0299","article-title":"Self-reports of prescription opioid abuse and diversion among recreational opioid users in a Canadian and a United States city.","volume":"11","author":"Setnik","year":"2015","journal-title":"J Opioid Manag"},{"key":"zoi241449r37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jsat.2019.07.005","article-title":"Buprenorphine in the United States: motives for abuse, misuse, and diversion.","volume":"104","author":"Chilcoat","year":"2019","journal-title":"J Subst Abuse Treat"},{"issue":"6","key":"zoi241449r38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups.","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"key":"zoi241449r40","doi-asserted-by":"publisher","first-page":"h1258","DOI":"10.1136\/bmj.h1258","article-title":"Process evaluation of complex interventions: Medical Research Council guidance.","volume":"350","author":"Moore","year":"2015","journal-title":"BMJ"},{"issue":"3","key":"zoi241449r41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/17439760.2016.1262613","article-title":"Thematic Analysis.","volume":"12","author":"Clarke","year":"2016","journal-title":"J Posit Psychol"},{"issue":"3","key":"zoi241449r42","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.addbeh.2006.05.022","article-title":"Motives, diversion and routes of administration associated with nonmedical use of prescription opioids.","volume":"32","author":"McCabe","year":"2007","journal-title":"Addict Behav"},{"issue":"1","key":"zoi241449r43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt\u2019s like \u2018liquid handcuffs\u201d: the effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives.","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduct J"},{"issue":"13","key":"zoi241449r44","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain\u2013misconceptions and mitigation strategies.","volume":"374","author":"Volkow","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi241449r46","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1093\/pubmed\/fdv150","article-title":"Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience.","volume":"38","author":"Wright","year":"2016","journal-title":"J Public Health (Oxf)"},{"key":"zoi241449r1","unstructured":"Ahmad? F, Cisewski? J, Rossen? L, Sutton? P. Provisional drug overdose death counts. National Center for Health Statistics. 2024. Accessed November 6, 2024. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"zoi241449r11","unstructured":"Canadian Association of People who use Drugs. Safe Supply Concept Document. 2019. Accessed November 11, 2024. https:\/\/vancouver.ca\/files\/cov\/capud-safe-supply-concept-document.pdf"},{"key":"zoi241449r39","unstructured":"Government of Ontario. Data standards for the identification and monitoring of systematic racism. Accessed November 11, 2024. https:\/\/files.ontario.ca\/solgen_data-standards-en.pdf"},{"key":"zoi241449r45","unstructured":"BC Centre on Substance Use. Clinical care guidance: prescribed safer supply. 2024. Accessed November 6, 2024. https:\/\/www.bccsu.ca\/clinical-care-guidance\/prescribed-safer-supply\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2828220\/olding_2024_oi_241449_1733863942.18662.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T16:00:44Z","timestamp":1734537644000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2828220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.51988","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]}}}